| 1 (44) | Samsung Corp * | MUL |  |
| 2 (89) | AstraZeneca * | MUL | |
| 3 (105) | Sanofi, United States | USA | |
| 4 (109) | Hypertension Arterielle, Pulmonaire: Physiopathologie et Innovation Therapeutique | FRA | |
| 5 (130) | GlaxoSmithKline * | MUL | |
| 6 (132) | AstraZeneca, United States | USA | |
| 7 (135) | Merck & Co Inc, United States | USA | |
| 8 (136) | Merck & Co Inc * | MUL | |
| 9 (140) | Hoffmann-La Roche Ltd, United States | USA | |
| 10 (141) | AstraZeneca, United Kingdom | GBR | |
| 11 (142) | Genentech Inc | USA | |
| 12 (146) | Sanofi * | MUL | |
| 13 (151) | Regeneron Pharmaceuticals Inc * | USA | |
| 14 (174) | F Hoffmann-La Roche * | MUL | |
| 15 (186) | Bayer * | MUL | |
| 16 (210) | Pfizer Inc, United States | USA | |
| 17 (220) | AstraZeneca, Sweden | SWE | |
| 18 (224) | Banco Bilbao Vizcaya Argentaria * | MUL | |
| 19 (230) | Banco Bilbao Vizcaya Argentaria, Spain | ESP | |
| 20 (248) | Boehringer Ingelheim * | MUL | |
| 21 (277) | GlaxoSmithKline, United Kingdom | GBR | |
| 22 (281) | GlaxoSmithKline, United States | USA | |
| 23 (285) | Pfizer * | MUL | |
| 24 (296) | Boehringer Ingelheim GmbH Germany | DEU | |
| 25 (299) | Sanofi, France | FRA | |
| 26 (375) | Robert Bosch * | MUL | |
| 27 (389) | CaixaBank SA * | ESP | |
| 28 (432) | Bosch, Germany | DEU | |
| 29 (525) | Novartis * | MUL | |
| 30 (576) | Boehringer Ingelheim, USA | USA | |
| 31 (593) | Janssen Biotech Inc | USA | |
| 32 (655) | Janssen | MUL | |
| 33 (668) | Johnson & Johnson * | MUL | |
| 34 (737) | Amgen * | MUL | |
| 35 (863) | Novartis Pharmaceuticals, United States | USA | |
| 36 (909) | Novartis, Switzerland | CHE | |
| 37 (1006) | IQVIA Inc * | MUL | |
| 38 (1157) | Amgen, USA | USA | |
| 39 (1369) | Takeda Pharmaceuticals International Inc * | MUL | |
| 40 (1388) | Takeda Pharmaceuticals International Inc, USA | USA | |
| 41 (1445) | Manipal Global Education Group * | MUL | |
|
